Aster DM Healthcare Limited has announced a scheduled board meeting to deliberate on interim dividend declaration for the current financial year. The healthcare company has informed stock exchanges about this significant corporate action through a formal communication dated March 20, 2026.

Board Meeting Details

The company's Board of Directors will convene on Thursday, March 26, 2026, with the primary agenda being consideration and approval of interim dividend declaration for Financial Year 2025-26. This meeting has been scheduled in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

As part of compliance with insider trading prevention measures, Aster DM Healthcare has implemented a trading window closure. The trading window was closed from March 19, 2026, and will remain closed until 48 hours after the announcement of financial results for the quarter and year ended March 31, 2026. This closure is in accordance with the company's code of conduct for prevention of insider trading.

Record Date and Payment

The company has established Friday, April 3, 2026, as the record date for payment of interim dividend, contingent upon board approval. Shareholders holding shares on the record date will be eligible to receive the interim dividend if declared by the board during the scheduled meeting.

Regulatory Compliance

The announcement demonstrates Aster DM Healthcare's commitment to maintaining transparency and regulatory compliance. The formal communication was signed by Hemish Purushottam, Company Secretary and Compliance Officer, and submitted to both BSE Limited and The National Stock Exchange of India Limited as required under listing regulations.

Aster DM Healthcare has received a positive rating revision from Kotak Institutional Equities, which has reinstated its Add recommendation on the healthcare provider with an ambitious target price of ₹725.

Growth Projections Post Quality Care Merger

The brokerage firm expects strong financial performance following the completion of the Quality Care merger, projecting robust growth metrics for the combined entity.

Key Growth Drivers

Kotak's optimistic outlook is supported by several strategic advantages that the merged entity is expected to leverage:

• Operational Synergies: Enhanced efficiency through combined operations and shared resources
• Enhanced Oncology Services: Strengthened cancer care capabilities driving higher revenue per patient
• Improved Payor Mix: Better insurance and corporate client portfolio leading to improved realizations
• Reduced ALOS: Lower Average Length of Stay indicating operational efficiency improvements
• Strong Balance Sheet: Robust financial position supporting growth initiatives

Expansion Strategy and Capacity Addition

The company's growth strategy includes significant capacity expansion through a well-planned bed addition program. Aster DM Healthcare plans to add 4,342 beds to its existing network, with approximately 60% of this expansion coming through brownfield projects.

This expansion approach, with its emphasis on brownfield development, is expected to provide faster implementation timelines and better return on investment compared to greenfield projects. The strategic bed addition program positions the healthcare provider for sustained growth over the coming years, supporting Kotak's positive long-term outlook on the stock.